PDCD1 and Obesity: The results of this study support the preclinical findings23,24,37,38,39 suggesting that patients with obesity may exhibit inadequate therapeutic responses to anti-PD-1 therapy, as shown in a U-shaped association between BMI and mortality in patients with aNSCLC who received ICI therapy (Figure 2B).